Published in Drug Des Devel Ther on July 21, 2010
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood (2012) 1.57
Current management of massive hemorrhage in trauma. Scand J Trauma Resusc Emerg Med (2012) 0.91
Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf (2011) 0.75
The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol (1961) 6.15
Acute traumatic coagulopathy. J Trauma (2003) 5.24
Early coagulopathy predicts mortality in trauma. J Trauma (2003) 3.97
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost (2004) 3.95
AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER. Nature (1964) 3.73
WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. Science (1964) 3.44
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion (2005) 2.76
Thrombin generation and fibrin clot structure. Blood Rev (2007) 2.37
A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med (1994) 2.22
Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg (1999) 2.19
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost (2004) 1.87
A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma (2008) 1.79
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood (2006) 1.78
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia (2007) 1.71
Effect of Haemostatic Control Resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang (2009) 1.69
What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol (2005) 1.68
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost (2007) 1.53
Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol (1997) 1.43
Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma (1997) 1.42
Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost (2007) 1.41
Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med (2009) 1.38
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost (2006) 1.25
Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth (1995) 1.23
Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost (2005) 1.19
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost (2001) 1.17
Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol (2006) 1.15
European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia (2007) 1.14
The use of recombinant activated factor VII in platelet disorders: a critical review of the literature. Blood Transfus (2009) 1.13
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia (2005) 1.12
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost (2001) 1.12
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost (1997) 1.12
Endothelial cell apoptosis in sepsis. Crit Care Med (2002) 1.11
Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost (1998) 1.10
Predictive model for survival at the conclusion of a damage control laparotomy. Am J Surg (2000) 1.10
Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost (2002) 1.09
Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia (2008) 1.08
A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia (2006) 1.08
Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia (2007) 1.08
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost (2006) 1.07
Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia (2005) 1.05
An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med (2006) 1.04
The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth (2006) 0.98
Transfusion packages for massively bleeding patients: the effect on clot formation and stability as evaluated by Thrombelastograph (TEG). Transfus Apher Sci (2008) 0.97
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med (1981) 0.94
The incidence of inhibitor development according to specific mutations--and treatment? Blood Coagul Fibrinolysis (2003) 0.93
Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol (1999) 0.91
Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg (1994) 0.90
Haemophilia care then, now and in the future. Haemophilia (2009) 0.89
A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol (2003) 0.88
Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol (1999) 0.88
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood (2002) 0.87
Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. Anaesth Intensive Care (1994) 0.85
Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia (2001) 0.84
Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia (2002) 0.84
Total joint replacement in patients with inhibitors. Haemophilia (2006) 0.83
Evolving role of tissue factor and its pathway inhibitor. Crit Care Med (2002) 0.83
Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Platelets (2006) 0.82
Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. The European Socioeconomic Study Group. Haemophilia (1998) 0.82
Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol (1994) 0.81
Elective orthopaedic surgery for inhibitor patients. Haemophilia (2003) 0.81
Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review. J Extra Corpor Technol (2006) 0.80
Recombinant factor VIIa to prevent surgical bleeding in factor XI deficiency. Haemophilia (2008) 0.80
FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia (2009) 0.79
Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion (1999) 0.79
Single-dose (270 microg kg(-1)) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia (2009) 0.79
Changes in transfusion therapy guided by thromboelastograph in cardiac surgery. Ann Card Anaesth (2001) 0.77
Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia (2007) 0.77
Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis (1996) 0.76
Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents. Transfus Apher Sci (2008) 0.76
Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med (2009) 1.38
Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets. Transfusion (2013) 1.35
Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care (2011) 1.26
Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS (2007) 1.11
Hemostatic resuscitation with plasma and platelets in trauma. J Emerg Trauma Shock (2012) 1.08
Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One (2013) 1.00
The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis (2011) 0.97
T-cell subset distribution in HIV-1-infected patients after 12 years of treatment-induced viremic suppression. J Acquir Immune Defic Syndr (2012) 0.97
Acute myocardial infarction is associated with endothelial glycocalyx and cell damage and a parallel increase in circulating catecholamines. Crit Care (2013) 0.96
Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J Infect Dis (2005) 0.95
Blood product ratio in acute traumatic coagulopathy--effect on mortality in a Scandinavian level 1 trauma centre. Scand J Trauma Resusc Emerg Med (2010) 0.92
Current management of massive hemorrhage in trauma. Scand J Trauma Resusc Emerg Med (2012) 0.91
Coagulopathy and hemostatic monitoring in cardiac surgery: an update. Scand Cardiovasc J (2012) 0.88
Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury. J Trauma Acute Care Surg (2014) 0.88
Blood levels of histone-complexed DNA fragments are associated with coagulopathy, inflammation and endothelial damage early after trauma. J Emerg Trauma Shock (2013) 0.87
The prognostic value of thrombelastography in identifying neurosurgical patients with worse prognosis. Blood Coagul Fibrinolysis (2011) 0.84
The influence of low platelet count on whole blood aggregometry assessed by Multiplate. Clin Appl Thromb Hemost (2011) 0.84
Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation. AIDS (2013) 0.84
Effect of valproic acid and injury on lesion size and endothelial glycocalyx shedding in a rodent model of isolated traumatic brain injury. J Trauma Acute Care Surg (2014) 0.82
Elderly trauma patients have high circulating noradrenaline levels but attenuated release of adrenaline, platelets, and leukocytes in response to increasing injury severity. Crit Care Med (2012) 0.82
Changes in fibrinogen availability and utilization in an animal model of traumatic coagulopathy. Scand J Trauma Resusc Emerg Med (2013) 0.82
Self-reported fatigue common among optimally treated HIV patients: no correlation with cerebral FDG-PET scanning abnormalities. Neuroimmunomodulation (2006) 0.82
Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol (2014) 0.81
Platelet aggregation following trauma: a prospective study. Blood Coagul Fibrinolysis (2014) 0.81
Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation (2010) 0.80
Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. Am J Trop Med Hyg (2008) 0.80
A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion (2012) 0.79
Marker of Endothelial Dysfunction Asymmetric Dimethylarginine Is Elevated in HIV Infection but Not Associated With Subclinical Atherosclerosis. J Acquir Immune Defic Syndr (2016) 0.77
Fresh-frozen plasma resuscitation after traumatic brain injury and shock attenuates extracellular nucleosome levels and deoxyribonuclease 1 depletion. Surgery (2013) 0.77
In-vitro comparison of free oscillation rheometry (ReoRox) and rotational thromboelastometry (ROTEM) in trauma patients upon hospital admission. Blood Coagul Fibrinolysis (2012) 0.77
High syndecan-1 levels in acute myeloid leukemia are associated with bleeding, thrombocytopathy, endothelial cell damage, and leukocytosis. Leuk Res (2013) 0.76
Hypercoagulability in response to elevated body temperature and central hypovolemia. J Surg Res (2013) 0.76
Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients. Ann Surg (2017) 0.76
A review of the clinical utility of INR to monitor and guide administration of prothrombin complex concentrate to orally anticoagulated patients. Thromb J (2012) 0.76
Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: comparison of prostacyclin vs. heparin prefilter administration. Blood Coagul Fibrinolysis (2010) 0.76
Haemostatic resuscitation in trauma: the next generation. Curr Opin Crit Care (2016) 0.76
Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. Shock (2017) 0.75
Early Identification of the Patient with Endotheliopathy of Trauma by Arrival Serum Albumin. Shock (2017) 0.75
The effect of intraoperative and 6-h postoperative intravenous administration of low-dose prostacyclin on the endothelium, hemostasis, and hemodynamics in patients undergoing a pancreaticoduodenoctemy: a randomized-controlled pilot study. Eur J Gastroenterol Hepatol (2016) 0.75
Dabigatran and its reversal with recombinant factor VIIa and prothrombin complex concentrate: a Sonoclot in vitro study. Scand J Clin Lab Invest (2014) 0.75
High Plasma Levels of Neuropeptide Y Correlate With Good Clinical Outcome But are not Correlated to Cerebral Blood Flow or Vasospasm After Subarachnoid Hemorrhage. J Neurosurg Anesthesiol (2016) 0.75